Cantitate/Preț
Produs

Novel Inhibitors of Leukotrienes: Progress in Inflammation Research

Editat de Giancarlo Folco, Bengt Samuelsson, Robert C. Murphy
en Limba Engleză Hardback – sep 1999
Many new antileukotriene drugs are now marketed as antiasthma drugs and represent the first new drugs in this field since the 1970s. This book covers the steps that have led to the discovery and development of these new drugs and offers detailed descriptions of their clinical applications. The review chapters on the main aspects of basic and applied leukotriene research are written by leading specialists in the field, and the volume takes a new approach in presenting information of particular interest to both scientists and clinicians in the fields of asthma, inflammation and allergic diseases.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 141335 lei  6-8 săpt.
  Birkhäuser Basel – 23 oct 2012 141335 lei  6-8 săpt.
Hardback (1) 142049 lei  6-8 săpt.
  Birkhäuser Basel – sep 1999 142049 lei  6-8 săpt.

Din seria Progress in Inflammation Research

Preț: 142049 lei

Preț vechi: 149525 lei
-5% Nou

Puncte Express: 2131

Preț estimativ în valută:
27188 28277$ 22784£

Carte tipărită la comandă

Livrare economică 13-27 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783764358846
ISBN-10: 376435884X
Pagini: 364
Ilustrații: XII, 347 p.
Dimensiuni: 155 x 235 x 25 mm
Greutate: 0.69 kg
Ediția:1999
Editura: Birkhäuser Basel
Colecția Birkhäuser
Seria Progress in Inflammation Research

Locul publicării:Basel, Switzerland

Public țintă

Professional/practitioner

Cuprins

5-Lipoxygenase.- LTC4 synthase: A key enzyme in cysteinyl leukotriene formation.- Leukotriene A4 hydrolase: A key enzyme in chemotactic leukotriene formation.- Metabolism of leukotrienes and formation of new leukotriene structures.- Receptors for cysteinyl-leukotrienes: Targets for new drugs.- Targeted disruption of 5-lipoxygenase.- Transcellular biosynthesis of leukotrienes: A unique mode of cell communication.- Physiological and pathophysiological activities of leukotrienes.- Entry rate and metabolic handling of LTC4 in the human circulation.- Genetic polymorphisms of 5-LO.- Leukotrienes and aspirin-intolerant asthma.- Leukotrienes in nocturnal asthma.- Leukotrienes and allergic asthma.- Inhibitors of leukotrienes: An overview.- The development of zafirlukast (Accolate®) and the Zeneca series of peptidyl-leukotriene receptor antagonists.- The development of zileuton (ZYFLO®) and the N-hydroxyurea class of 5-lipoxygenase inhibitors.- The development of BAY X 1005 and the Bayer series of leukotriene biosynthesis inhibitors.- The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists.- LTB4 receptor antagonists.- SmithKline Beecham pharmaceuticals’ cysteinyl leukotriene receptor antagonists: Pranlukast (SB 205312; Ono-1078; Onon), Pobilukast (SK&F 104353) and SK&F 106203.